Cargando…

Selective Laser Trabeculoplasty in Egyptian Patients with Primary Open-Angle Glaucoma

PURPOSE: To assess the change in intraocular pressure (IOP) in Egyptian patients after selective laser trabeculoplasty (SLT) as a primary or adjunctive treatment for primary open-angle glaucoma (POAG). MATERIALS AND METHODS: One hundred and six eyes with POAG were enrolled in this prospective study....

Descripción completa

Detalles Bibliográficos
Autores principales: Abdelrahman, Ahmed M., Eltanamly, Rasha M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401799/
https://www.ncbi.nlm.nih.gov/pubmed/22837623
http://dx.doi.org/10.4103/0974-9233.97930
Descripción
Sumario:PURPOSE: To assess the change in intraocular pressure (IOP) in Egyptian patients after selective laser trabeculoplasty (SLT) as a primary or adjunctive treatment for primary open-angle glaucoma (POAG). MATERIALS AND METHODS: One hundred and six eyes with POAG were enrolled in this prospective study. Patients were divided into two groups: recently diagnosed cases with no preoperative medications (group 1) and; patients with confirmed glaucoma on medical therapy (group 2). All patients underwent 360° SLT. Patients were evaluated to 18 months postoperatively. Data were analyzed on postoperative changes in IOP, number of medications and complications. A P-value less than 0.05 was statistically significant. RESULTS: A statistically significant drop in IOP occurred, from 19.55 ± 4.8 mmHg preoperatively, to16.03 ± 2.8 mmHg postoperatively (P< 0.001). Each group had a statistically significant drop in IOP (P< 0.001). There was a statistically significant decrease in the number of medications in group 2 from 2.25 ± 0.97 medications preoperatively to 1.0 ± 1.3 medications postoperatively (P=0.004). No serious complications occurred for the duration of the study. CONCLUSION: SLT can be safely and effectively used as primary or adjunctive therapy for the treatment of POAG.